| Reference |
 |
Unresectable Locally Advance or Stage IV: ECOG E2607
| Title |
|
DASATINIB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR STAGE IV MUCOSAL, ACRAL AND VULVOVAGINAL MELANOMAS
| Description |
|
ELIGIBILITY
- Histologically or cytologically confirmed melanoma of 1 of the following subtypes:
- Acral melanoma (defined as occurring on the palms, soles, or subungual sites)
- Melanoma arising from the vagina and/or vulva
- Melanoma arising on other mucosal surface (not vagina or vulva)
- Unresectable locally advanced or metastatic disease
- c-KIT mutation identified by polymerase chain reaction (PCR) and sequencing
- Measurable disease
- No ocular melanoma
TREATMENT
Patients will receive dasatinib 70 mg to be taken by mouth twice daily. The medication is to be taken once in the morning and once in the evening with or without food. The cycle length of dasatinib is 21 days.
| Additional Info |
|
On the web: http://www.clinicaltrials.gov/ct2/search
|
